Flag­ship aims to raise $3B; Phe­nom­ic inks an­oth­er phar­ma deal; On­covi­ta gets €8M for can­cer vac­cine

Flag­ship Pi­o­neer­ing eyes $3B fund: The Mod­er­na cre­ator and in­cu­ba­tor of more than 100 star­tups seeks to raise its eighth fund, per a Wednes­day SEC fil­ing. The move comes as the Boston firm ex­pands to the UK and Asia-Pa­cif­ic. Its last fund was a $3.4 bil­lion haul in June 2021. — Kyle LaHu­cik

Phe­nom­ic AI an­nounces sec­ond phar­ma deal: The biotech said Thurs­day that it’s work­ing with Astel­las Phar­ma to fig­ure out whether Phe­nom­ic’s an­ti­bod­ies can en­hance cell ther­a­pies when treat­ing pa­tients with sol­id tu­mors. Fi­nan­cial terms of the deal were not dis­closed. Ear­li­er this week, Boehringer In­gel­heim said it’s pay­ing Phe­nom­ic $9 mil­lion up­front, plus mile­stones worth up to $500 mil­lion, in a bid to find new tar­gets for cer­tain can­cers. — Jaimy Lee

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.